Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2952W HIGH $20.00
Volume
15.79 K
Value Traded
83.15 K
Short % Float
3.27%
-8.25%Week
-23.48%1 Month
-17.29%3 Month
-61.78%6 Month
-97.99%5 Year
-98.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.16 M
EPS (TTM)
-11.22
P/E Ratio
-
Ent. Value
-11.99 M
Total Shares
3.22 M
Float Shares
2.97 M
Insiders
7.71%
Institutions
43.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PASG Catalyst Timeline
Dated clinical, regulatory and corporate events for Passage Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Passage Bio, Inc.
379Total events
2Upcoming
73Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Development Candidate NominationPreclinical
Declare clinical candidate for Huntington's disease
Huntington's diseasesource ↗
▼Equity OfferingCorporate
Concurrent oversubscribed $100 million private placement financing for Remix
▲Full ResultsPBFT02Clinical Data
Updated interim data from upliFT-D trial showing improvements in biomarkers
frontotemporal dementia with GRN mutationssource ↗
●Type C MeetingPBFT02FDA Meeting
Completed Type C meeting with FDA regarding registrational trial design
frontotemporal dementia with GRN mutationssource ↗
▼FDA Feedback ReceivedPBFT02FDA Meeting
FDA feedback from Type C meeting: randomized controlled trial required
frontotemporal dementia with GRN mutationssource ↗
◆Pipeline PrioritizationPBFT02Corporate
Evaluating potential next steps for PBFT02 clinical development program
frontotemporal dementia with GRN mutationssource ↗
▲First Patient DosedPBFT02Trial
Treated first FTD-C9orf72 patient with Dose 2 in Cohort 4
FTD-C9orf72source ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference presentation
◆Timing GuidancePBFT02Presentation
On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026
FTD-GRNsource ↗
◆FDA Feedback ReceivedPBFT02FDA Meeting
Seek regulatory feedback on FTD-GRN pivotal trial design
frontotemporal dementia with granulin mutationssource ↗
◆Topline ReadoutPBFT02Clinical Data
Report updated interim safety and biomarker data from Dose 2
FTD-GRNsource ↗
●Enrollment UpdatePBFT02Trial
Currently enrolling patients in Cohort 3 and Cohort 4 of upliFT-D trial
FTD-GRNsource ↗
◆Oral PresentationPresentation
Passage Bio to present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
◆Enrollment UpdatePBFT02Trial
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients
frontotemporal dementia (FTD-GRN and FTD-C9orf72)source ↗
▲FDA Feedback ReceivedPBFT02FDA Meeting
Aligned with FDA on analytical comparability plan for suspension-based manufacturing process
frontotemporal dementiasource ↗
◆Oral PresentationPresentation
Passage Bio CEO to participate in panel at Chardan 9th Annual Genetic Medicines Conference
◆Oral PresentationPresentation
Passage Bio management to present at H.C. Wainwright 27th Annual Global Investment Conference
▲Enrollment CompletePBFT02Trial
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study
FTD-GRNsource ↗
▲Full ResultsPBFT02Clinical Data
Reported updated interim data showing robust durable elevation in CSF PGRN and improvement in plasma NfL
FTD-GRNsource ↗
●Protocol AmendmentPBFT02Trial
Submitted amended upliFT-D study protocol to global trial sites and health authorities
FTD-GRNsource ↗
▼Reverse Stock SplitCorporate
1-for-20 reverse stock split approved by Board, effective July 14, 2025
●Protocol AmendmentPBFT02Trial
Plan to amend upliFT-D protocol to include prophylactic anticoagulation and modify inclusion criteria
frontotemporal dementia with granulin mutationssource ↗
●Enrollment UpdatePBFT02Trial
Plan to begin enrollment in Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) after protocol amendment acceptance
frontotemporal dementia with granulin mutationssource ↗
●Trial InitiationPBFT02Trial
Initiation of enrollment of first FTD-C9orf72 patient cohort
FTD-C9orf72source ↗
▲Full ResultsPBFT02Clinical Data
Updated interim data from upliFT-D study showing robust CSF PGRN elevation and reduced plasma NfL
frontotemporal dementia with granulin mutationssource ↗
▲Interim AnalysisPBFT02Trial
Interim data from upliFT-D trial presented (data cutoff June 15, 2025)
FTD-GRNsource ↗
◆Timing GuidancePBFT02Presentation
Plan to deliver meaningful data over the next twelve months
frontotemporal dementia (FTD-GRN)source ↗
▲First Patient DosedPBFT02Trial
Treated first FTD-GRN patient with Dose 2 PBFT02
frontotemporal dementia (FTD-GRN)source ↗
▲Enrollment UpdatePBFT02Trial
Enrolled second FTD-GRN patient in upliFT-D trial
frontotemporal dementia (FTD-GRN)source ↗
●Poster PresentationPBFT02Presentation
Presentation of process development data for PBFT02 at ASGCT 28th Annual Meeting
◆Topline ReadoutPBFT02Clinical Data
Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2
FTD-GRNsource ↗
◆Timing GuidancePBFT02Presentation
Expect to deliver additional data from upliFT-D in second half of 2025
frontotemporal dementia (FTD-GRN)source ↗
▲Interim AnalysisPBFT02Trial
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels
FTD-GRNsource ↗
▲First Patient DosedPBFT02Trial
Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02
FTD-GRNsource ↗
▲Enrollment UpdatePBFT02Trial
Expanding enrollment to include FTD patients with C9orf72 gene mutations
FTD-C9orf72source ↗
Past FDA Catalysts and PDUFA Decisions
How PASG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | PBFT02 | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F18 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 96%
Micro Cap(rank 632 of 658)
Percentile Rank
Passage Bio, Inc. has significant pipeline risk (18/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PBFT02 Small moleculeNCT04747431 | Frontotemporal Dementia | Phase 1 | ACTIVE NOT_RECRUITING | 30 | Aug 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every PASG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PBFT02 | frontotemporal dementia with granulin mutations | Phase 1/2 | 2026-04-20 | whole brain atrophy reduction: 64%; atrophy at 12 months treated: 3.1%; atrophy at 12 months natural history: 8.7%Read More | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP10% Owner | Buy | 50,055 673,759 held | $4.12 | 06/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PASG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % | 485.00 K | 99.52 K | 46.08% ( 31.39 K) |
PASG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PASG ranks across every disease it competes in
Competitive Position is a premium feature
See how PASG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPASG News
PASG▼ -26.4%on this news
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio and Remix Therapeutics have announced a merger agreement to form a new entity focused on RNA processing therapies. The combined company will operate under the name Remix Therapeutics and aims to advance its lead program, REM-422, targeting MYB in various cancers. A concurrent $100 million financing is expected to fund operations through 2028, supporting key clinical milestones. The merger is anticipated to close in Q4 2026, subject to regulatory approvals.
Read more →PASG▼ -46.4%on this news
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Passage Bio reported positive interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing improvements in biomarkers of frontotemporal dementia with granulin mutations. However, the FDA has mandated a randomized controlled trial for further development, presenting challenges for the company. Passage Bio is also undergoing a strategic review to enhance shareholder value.
Read more →PASG▼ -8.9%on this news
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported its financial results for Q4 and full year 2025, highlighting progress in its clinical programs for frontotemporal dementia and Huntington's disease. The company successfully enrolled patients in its upliFT-D study and plans to report interim data and seek regulatory feedback in 2026. Despite a net loss, the company maintains a cash runway through Q1 2027.
Read more →PASGPassage Bio to Participate in Upcoming Investor Conferences
Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. The company's management will give presentations and participate in investor meetings on February 26, 2026, and March 4, 2026, respectively, in Boston, MA. Passage Bio focuses on therapies for neurodegenerative diseases, particularly their lead candidate PBFT02, aimed at enhancing progranulin levels to slow disease progression.
Read more →PASG▲ +10.3%on this news· ran to +73% by day 3
Passage Bio. All rights reserved. Corporate Presentation Redefining the Course of Neurodegenerative Conditions January 2026 Forward - Looking Statement This presentation includes "forward - looking statements" within the
Passage Bio has presented forward-looking statements regarding the development of its gene therapy candidate, PBFT02, aimed at treating Frontotemporal Dementia (FTD) caused by GRN mutations. The company highlighted potential benefits, including promising early clinical trial data and regulatory designations that position PBFT02 as a leading therapy in its class. However, the company acknowledged various risks associated with regulatory approvals, clinical trial management, and dependencies on external collaborators. Overall, Passage Bio aims to redefine treatment for neurodegenerative conditions while maintaining financial stability through expected cash reserves.
Read more →PASG▲ +14.8%on this news· ran to +40% by day 1
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported its third quarter 2025 financial results, highlighting active enrollment in new patient cohorts for its upliFT-D study. The company has successfully aligned with the FDA on its PBFT02 manufacturing process and is on track to receive regulatory feedback on trial design in the first half of 2026. Passage Bio's cash runway extends into the first quarter of 2027, supporting ongoing clinical efforts.
Read more →PASGPassage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio, a clinical stage genetic medicines company, will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 12, 2025. CEO Will Chou will participate in a fireside chat, which will also be available via live webcast. The company focuses on developing therapies for neurodegenerative diseases, particularly through its lead candidate PBFT02.
Read more →PASGPassage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
Passage Bio, Inc. will participate in the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025. CEO Will Chou will be part of a panel discussion in New York City. The event will be webcast live, with a replay available for 90 days. Passage Bio is focused on developing therapies for neurodegenerative diseases.
Read more →PASGPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Passage Bio, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Will Chou will present an overview of the company and engage in one-on-one meetings with investors. A video webcast of the presentation will be available for registered attendees, emphasizing the company's focus on advancing therapies for neurodegenerative diseases.
Read more →PASGPASSAGE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Passage Bio reported its financial results for the second quarter of 2025, highlighting significant progress in its upliFT-D clinical trial. The company completed dosing for Cohort 2 and reported encouraging interim data on PBFT02, which shows improved biomarkers for neurodegeneration. Passage Bio's financial position appears stable with a cash runway projected to extend through early 2027. Management anticipates further enrollment in upcoming cohorts as they continue to engage with health authorities on future regulatory pathways.
Read more →PASG▼ -9.9%on this news· ran to -32% by day 3
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio has announced a 1-for-20 reverse stock split, effective July 14, 2025, to comply with Nasdaq's minimum bid price requirement. This decision was approved by stockholders during the 2025 annual meeting. The reverse stock split will reduce the number of outstanding shares significantly, but will not affect stockholders' percentage ownership interests.
Read more →PASG▼ -14.4%on this news
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Passage Bio reported promising interim data from the Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia. The treatment demonstrated significant increases in cerebrospinal fluid progranulin levels and improvements in plasma neurofilament, indicating potential benefits for patients. The company plans to amend the trial protocol to enhance safety and broaden patient eligibility, with regulatory feedback anticipated in early 2026.
Read more →PASGPASSAGE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Passage Bio, Inc. has reported its first quarter financial results for 2025, highlighting key achievements in its ongoing clinical trials. The company has successfully treated its first patient with Dose 2 of PBFT02 and has enrolled a second patient, with more patients being evaluated. They also announced advancements in a high productivity manufacturing process for PBFT02, which was presented at a prominent industry meeting. Financially, Passage Bio indicates a cash runway that extends into the first quarter of 2027, reflecting its ongoing operational stability and commitment to developing therapies for neurodegenerative diseases.
Read more →PASG▼ -11.4%on this news
PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Passage Bio reported its fourth quarter and full-year financial results for 2024, demonstrating progress in its PBFT02 program. Interim data indicate positive outcomes, including elevated CSF PGRN levels and reduced plasma NfL levels, suggesting potential benefits in treating neurodegenerative diseases for FTD-GRN patients. The company has successfully developed a high-productivity manufacturing process and aims for continued enrollment in clinical trials. Passage Bio's cash runway has been extended into the first quarter of 2027, positioning the company well for future developments.
Read more →PASGPASSAGE BIO ANNOUNCES INTERIM DATA FROM UPLIFT-D STUDY IN FTD-GRN AND PROVIDES BUSINESS UPDATES
Passage Bio announced interim data from its ongoing Phase 1/2 upliFT-D clinical trial evaluating the gene therapy PBFT02 for patients with frontotemporal dementia (FTD) associated with granulin mutations. The data indicated a significant increase in cerebrospinal fluid (CSF) PGRN levels and suggested potential reductions in plasma NfL levels, which correlate with disease progression. The company also revealed plans to transition to an outsourced testing model, extending its financial runway through Q1 2027, while ongoing trials continue to assess safety and efficacy.
Read more →PASG▼ -12.9%on this news· ran to -29% by day 3
PASSAGE BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohor
Passage Bio reported its financial results for the third quarter of 2024, highlighting advancements in its PBFT02 gene therapy program. During the quarter, the company enrolled four patients in the upliFT-D trial for FTD-GRN, with dosing on schedule. Updated interim data from the ongoing trial indicated the therapy was well-tolerated and effectively raised CSF progranulin levels. The company maintains a robust cash position, ensuring operational continuity into mid-2026 amidst ongoing challenges in clinical trials and regulatory pathways.
Read more →PASGPassage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio, a clinical stage genetic medicines company, announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024. CEO Will Chou, M.D. will deliver a presentation about the company's focus on advancing therapies for neurodegenerative diseases. The company's lead candidate, PBFT02, aims to treat conditions like frontotemporal dementia. A live webcast of the presentation will be available on their website, along with a 30-day replay afterwards.
Read more →PASG▲ +11.4%on this news
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31 st Annual Conference Preclinical data demonstrated that an AAV1 vector achieved s
Passage Bio presented positive preclinical and interim clinical data for its gene therapy PBFT02 at the ESGCT Annual Conference. The AAV1 vector demonstrated superior elevation of human progranulin levels compared to other vectors. The therapy showed promising results in improving lysosomal function and reducing neuroinflammation in preclinical models, as well as a good safety profile in ongoing clinical trials. These findings position PBFT02 as a potentially best-in-class therapy for frontotemporal dementia with GRN mutations.
Read more →PASG▼ -5.1%on this news
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Passage Bio, a clinical stage genetic medicines company, announced that its CEO, Dr. Will Chou, will present at Chardan’s 8th Annual Genetic Medicines Conference on October 1, 2024. The company focuses on developing therapies for neurodegenerative diseases, with its lead product candidate, PBFT02, targeting conditions like frontotemporal dementia. A live webcast of the presentation will be available, along with a replay for 30 days afterwards. This event highlights the company's commitment to advancing treatment options in the genetic medicine arena.
Read more →About Passage Bio, Inc.
HeadquartersONE COMMERCE SQUARE, PHILADELPHIA, PA, 19103
BIOPHARMAWATCH ELITE PLUS
Trade the next PASG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime